-
www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/patient-safety-resources/resources/advances-in-patient-safety/vol1/Weinberg.pdf
March 01, 2004 - All
Reporter protections 6
Designated review bodies and sanctioning authority 5
Computerized drug
-
www.ahrq.gov/sites/default/files/wysiwyg/data/SyH-DR-PUF-Summary-Statistics-Medicaid-Inpatient-Weighted.pdf
September 26, 2023 - 0.00 7,313,787 84.27
86: Neuropsychiatry 4,482 0.05 7,318,269 84.33
87: All other suppliers (e.g., drug
-
www.ahrq.gov/sites/default/files/wysiwyg/sops/surveys/nursing-home/nursinghome-resourcelist.pdf
April 01, 2023 - psnet.ahrq.gov/primers/primer/23
A growing evidence base supports specific strategies to prevent adverse drug
-
www.ahrq.gov/patient-safety/settings/hospital/fall-prevention/toolkit/practices.html
January 01, 2013 - Or, if attendance on rounds is not possible, pharmacists can place recommendations to change drug therapy
-
www.ahrq.gov/sites/default/files/2025-03/chaudhry-report.pdf
January 01, 2025 - Final Progress Report: Yale Center for Healthcare Innovation, Redesign, and Learning (CHIRAL)
Final Progress Report
Project Title: Yale Center for Healthcare Innovation, Redesign, and Learning (CHIRAL)
PI: Sarwat I. Chaudhry
Yale University
Inclusive Dates: 9/30/2014-9/29/2019
Agency for Healthcare Research and Qua…
-
www.ahrq.gov/healthsystemsresearch/hspc-research-study/research-gaps.html
June 01, 2020 - 6. Research Gaps and Prioritization of Federally Funded HSR and PCR
Health Services and Primary Care Research Study: Comprehensive Report
One of the study’s key research questions focuses on identifying research gaps—understudied or underfunded areas in HSR and PCR that, if addressed, would move the fields fo…
-
www.ahrq.gov/sites/default/files/wysiwyg/professionals/systems/hospital/nicu_toolkit/nicupacket-apb.pdf
December 10, 2013 - Transitioning Newborns from NICU to Home: Family Information Packet, Appendix B
Appendix B: Clinical Materials to Share
With Primary Care Providers
Diagnoses and Conditions
■ Anemia of Prematurity
■ Apnea of Prematurity
■ Bronchopulmonary Dysplasia
■ Gastroesophageal Reflux
■ Nephrocalcinosis
■ Patent D…
-
www.ahrq.gov/sites/default/files/publications2/files/building-state-cooperatives-meeting-summary.pdf
September 26, 2024 - Building State Cooperatives for Healthcare Improvement: Meeting Summary
Contents
Contents ..........................................................…
-
www.ahrq.gov/sites/default/files/wysiwyg/chsp/compendium/2022-Compendium-TechDoc.pdf
January 01, 2022 - In addition, IQVIA uses Drug Distribution Data that enable quick identification of new
organizations … ’s National Plan and Provider
Enumeration System (NPPES), State Controlled Substance Registration, Drug
-
www.ahrq.gov/sites/default/files/publications/files/toolkit.pdf
September 01, 2005 - • Call center—regional poison center, drug line for national companies, nurse advice
line, translation
-
www.ahrq.gov/sites/default/files/publications/files/implementation-guide_0.pdf
September 01, 2015 - asymptomatic bacteriuria can lead to antimicrobial resistance, Clostridium difficile infection,
and adverse drug
-
www.ahrq.gov/sites/default/files/publications/files/resphys-champions_2.pdf
September 01, 2015 - use, thus resulting in more antimicrobial resistance, Clostridium difficile
infection, and adverse drug
-
www.ahrq.gov/sites/default/files/publications/files/resphys-champions.pdf
September 01, 2015 - use, thus resulting in more antimicrobial resistance, Clostridium difficile
infection, and adverse drug
-
www.ahrq.gov/sites/default/files/wysiwyg/professionals/clinicians-providers/guidelines-recommendations/tobacco/clinicians/references/quickref/tobaqrg.pdf
April 01, 2009 - , MPH, CHES, National Heart, Lung, and Blood Institute
Stephen Heishman, PhD, National Institute on Drug
-
www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/hais/cauti-tools/impl-guide/implementation-guide.pdf
September 01, 2015 - asymptomatic bacteriuria can lead to antimicrobial resistance, Clostridium difficile infection,
and adverse drug
-
www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/hais/cauti-tools/guides/resphys-champions.pdf
September 01, 2015 - use, thus resulting in more antimicrobial resistance, Clostridium difficile
infection, and adverse drug
-
www.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/0085episiotomycoding.xls
January 01, 2012 - FFS
PHDSC 2.16.840.1.113883.221.5 Payer Individual Characteristic Source of Payment Typology 4.0 122 Drug
-
www.ahrq.gov/sites/default/files/wysiwyg/CHIPRA-BMI-Coding.xls
January 01, 2012 - FFS
PHDSC 2.16.840.1.113883.221.5 Payer Individual Characteristic Source of Payment Typology 4.0 122 Drug
-
www.ahrq.gov/sites/default/files/2024-12/dalton-report.pdf
January 01, 2024 - Under these conditions, safe treatment
options include expectant management and drug therapy to cause
-
www.ahrq.gov/sites/default/files/wysiwyg/hai/tools/clabsi-cauti-icu/playbook.pdf
April 01, 2022 - A Playbook for Preventing CLABSI and CAUTI in the ICU Setting
AHRQ Safety Program for Intensive Care
Units: Preventing CLABSI and CAUTI
A Playbook for Preventing
CLABSI and CAUTI in the
ICU Setting
2 Playbook
AHRQ Safety Program for Intensi…